@RoteBlume
90% #XFG sind beeindruckend. Ich dachte unsere 60% sind viel.

Here's the latest variant picture for Europe (excluding the UK), to the end of November.

BA.3.2.* "Cicada" showed a slightly slowing growth advantage of 7% per day (49% per week) over XFG.* "Stratus", which predicts a crossover in late December.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for Canada, to the end of November.

XFG.* "Stratus" continued to dominate, up slightly to 73%.

NB.1.8.1 "Nimbus" also rose, to 23%.

#COVID19 #SARSCoV2 #Canada #XFG #Stratus #NB_1_8_1 #Nimbus
🧵

Here's the latest variant picture for the United States, to the end of November.

The XFG.* "Stratus" variant continued it’s dominance, but fell to 81% frequency.

NB.1.8.1 "Nimbus" was up slightly to 9%.

#COVID19 #SARSCoV2 #USA #XFG #Stratus #NB_1_8_1 #Nimbus
🧵

Here's the latest variant picture for New Zealand, to early December.

In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus". This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for Europe (excluding the UK), to late November.

BA.3.2.* "Cicada" is showing a very strong growth advantage of 7.9% per day (55% per week) over XFG.* "Stratus", which predicts a crossover in late December.

To include the latest BA.3.2.* samples, I have rolled my reporting window forward an extra week or so. So the most recent data is even less representative than usual. The picture for those dates might change as more data is shared.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for Canada, to late November.

XFG.* "Stratus" continued to dominate, but fell to 67%.

NB.1.8.1 "Nimbus" rose slightly to 18%.

XFV.* grew to 10% nationally, however all the recent samples are from Ontario and recent volumes are very low, so that could just be a cluster from a healthcare or aged care setting.

#COVID19 #SARSCoV2 #Canada #XFG #Stratus #NB_1_8_1 #Nimbus #FLiRT
🧵

Here's the latest variant picture for the United States, to late November.

The XFG.* "Stratus" variant continued it’s dominance, up again to 84% frequency.

NB.1.8.1 "Nimbus" was down slightly to 8%.

#COVID19 #SARSCoV2 #USA #XFG #Stratus #NB_1_8_1 #Nimbus
🧵

Here's the latest variant picture for New Zealand, to late November.

In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus". This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for Europe (excluding the UK), to mid-November.

BA.3.2.* "Cicada" is showing continued signs of growth. Recent samples have been reported from Germany and Ireland.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for the United Kingdom, to mid-November.

The XFG.* "Stratus" variant remained dominant, steady at 80%.

NB.1.8.1 "Nimbus" fell to 13%.

#COVID19 #SARSCoV2 #UK #XFG #Stratus #NB_1_8_1 #Nimbus
🧵

Here's the latest variant picture for Canada, to mid-November.

XFG.* "Stratus" continued to dominate, roughly steady at 76%.

NB.1.8.1 "Nimbus" fell slightly to 17%.

#COVID19 #SARSCoV2 #Canada #XFG #Stratus #NB_1_8_1 #Nimbus #FLiRT
🧵

Here's the latest variant picture for the United States, to mid-November.

The XFG.* "Stratus" variant continued it’s dominance, down slightly to 80% frequency.

NB.1.8.1 "Nimbus" was up slightly to 9%.

#COVID19 #SARSCoV2 #USA #XFG #Stratus #NB_1_8_1 #Nimbus
🧵

Here's the latest variant picture with a global scope, to mid-November.

BA.3.2.* has continued to show signs of growth. Recent samples have been reported from South Africa, Australia, across Europe, and a traveller entering the US from Kenya.

#COVID19 #SARSCoV2 #Global #BA_3_2 #XFG #Stratus
🧵

Gebessert hat sich mMn die Darstellung der Virusvarianten von #SarsCoV2 im neuen #Abwassermonitoring. Grafisch viel übersichtlicher, auch weil Subvarianten zusammengefasst werden. Das ist für Hobbyvirologys völlig ausreichend. Uns reicht es, dass #XFG weiterhin bei weitem dominiert, aber langsam abnimmt. Ob es sich um XFG.3.4.2, XFG.22 oder XFG.9.1 handelt, ist wirklich was, das nur echte Virologys interessiert.

Here's the latest variant picture for Europe (excluding the UK), to early November.

BA.3.* (mostly BA.3.2.2) is showing continued signs of growth. Recent samples have been reported from Ireland.

Note I have held my reporting window to the same date as week, to revert to a lag point where recent samples are more representative.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for the United Kingdom, to early November.

The XFG.* "Stratus" variant remained dominant, rebounding to 79%.

NB.1.8.1 "Nimbus" fell to 18%.

#COVID19 #SARSCoV2 #UK #XFG #Stratus #NB_1_8_1 #Nimbus
🧵

Here's the latest variant picture for Canada, to early November.

XFG.* "Stratus" continued to dominate, but fell to 74%.

NB.1.8.1 "Nimbus" rose to 20%.

#COVID19 #SARSCoV2 #Canada #XFG #Stratus #NB_1_8_1 #Nimbus #FLiRT
🧵

Here's the latest variant picture for the United States, to early November.

The XFG.* "Stratus" variant continued it’s dominance, roughly flat at 83% frequency.

NB.1.8.1 "Nimbus" was down slightly to 7%.

#COVID19 #SARSCoV2 #USA #XFG #Stratus #NB_1_8_1 #Nimbus
🧵

Here's the latest variant picture for New Zealand, to mid-November.

In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus". This scenario raises the risk of rapid reinfections, for those relying on immunity from a recent infection.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵